Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F25%3A00010213" target="_blank" >RIV/00023884:_____/25:00010213 - isvavai.cz</a>

Výsledek na webu

<a href="https://thejns.org/view/journals/j-neurosurg/142/5/article-p1357.xml" target="_blank" >https://thejns.org/view/journals/j-neurosurg/142/5/article-p1357.xml</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3171/2024.7.JNS24920" target="_blank" >10.3171/2024.7.JNS24920</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis

Popis výsledku v původním jazyce

This study aimed to evaluate local control (LC) of tumors, patient overall survival (OS), and the safety of METHODS This retrospective cohort study used data from 15 International Radiosurgery Research Foundation facilities encompassing 67 patients with 185 EBMs managed using SRS between January 2000 and May 2022. The median patient age was 63 years, with a male predominance (92.5%). Most patients (64.2%) had a single brain metastasis, while 7.5% had more than 5 metastases. The median tumor volume was 0.9 cm3, and the median margin dose delivered to the tumor was 20 Gy. RESULTS The median OS post-SRS was 15.2 months, with 1-and 2-year OS rates of 65.7% and 32.3%, respectively. A significant inverse correlation was found between the number of EBMs and OS in the univariable analysis. LC rates at 1 and 2 years were 89% and 76%, respectively. Adverse radiation effects (AREs) were observed in 17.9% of patients, with 13.4% being mild and transient and 4.5% severely symptomatic (Common Terminology Criteria for Adverse Events grade 3). New intracranial disease developed in 58.2% of patients, with 1-and 2-year rates of 58% and 73%, respec-tively. CONCLUSIONS SRS for EBMs demonstrated high survival rates and effective tumor control, with a low incidence of severe AREs. These findings highlight the potential role of SRS in the multidisciplinary multimodality management para-digm of EBM.

Název v anglickém jazyce

Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis

Popis výsledku anglicky

This study aimed to evaluate local control (LC) of tumors, patient overall survival (OS), and the safety of METHODS This retrospective cohort study used data from 15 International Radiosurgery Research Foundation facilities encompassing 67 patients with 185 EBMs managed using SRS between January 2000 and May 2022. The median patient age was 63 years, with a male predominance (92.5%). Most patients (64.2%) had a single brain metastasis, while 7.5% had more than 5 metastases. The median tumor volume was 0.9 cm3, and the median margin dose delivered to the tumor was 20 Gy. RESULTS The median OS post-SRS was 15.2 months, with 1-and 2-year OS rates of 65.7% and 32.3%, respectively. A significant inverse correlation was found between the number of EBMs and OS in the univariable analysis. LC rates at 1 and 2 years were 89% and 76%, respectively. Adverse radiation effects (AREs) were observed in 17.9% of patients, with 13.4% being mild and transient and 4.5% severely symptomatic (Common Terminology Criteria for Adverse Events grade 3). New intracranial disease developed in 58.2% of patients, with 1-and 2-year rates of 58% and 73%, respec-tively. CONCLUSIONS SRS for EBMs demonstrated high survival rates and effective tumor control, with a low incidence of severe AREs. These findings highlight the potential role of SRS in the multidisciplinary multimodality management para-digm of EBM.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neurosurgery

ISSN

0022-3085

e-ISSN

—

Svazek periodika

142

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

1357-1365

Kód UT WoS článku

001488885700003

EID výsledku v databázi Scopus

2-s2.0-105004288442